Novavax will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination vaccine candidates at the World Vaccine Congress 2024 in Washington, DC, April 2 to 4, 2024. New data from Novavax’s ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant. Data also showed that the vaccine’s safety and reactogenicity profile was consistent with its prototype vaccine. Differences observed in immunoglobulin (IgG) subclass responses and Fcgamma-mediated effector functions following mRNA and protein-based COVID-19 vaccinations will be shared. Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial anticipated to start during the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Upcoming Deadline to Share in Novavax, Inc. (NVAX) Class Action Settlement
- Novavax discloses confidential settlement agreement with Fujifilm
- Novavax (NASDAQ:NVAX) Remains Highly Speculative, Post-Pandemic
- Novavax notes Canada’s National Advisory Committee on Immunization guidance
- Novavax price target lowered to $19 from $35 at H.C. Wainwright
